PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE ...

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...

PMV Pharmaceuticals (NASDAQ:PMVP) stock surged 16% after the company released encouraging interim results from its Phase 2 ...

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ...

PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.

PMV Pharmaceuticals ( ($PMVP) ) has provided an update. On September 10, 2025, PMV Pharmaceuticals announced interim data from their Phase 2 ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Investing.com -- PMV Pharmaceuticals (NASDAQ:PMVP) stock surged 16% after the company reported encouraging interim data from ...

Functional genomics, which is seeing how genetic variants behave in biological systems through genetic testing, is offering ...